Cost-Effectiveness of Modified Gemcitabine and Oxaliplatin for Gallbladder Cancer
Author Information
Author(s): Chen Zhaoyan, Tian Fangyuan
Primary Institution: National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University
Hypothesis
This study aims to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin for treating unresectable gallbladder cancer in China.
Conclusion
Modified gemcitabine coupled with oxaliplatin is not a cost-effective treatment option for unresectable gallbladder cancer in a Chinese healthcare context.
Supporting Evidence
- The utility value of modified oxaliplatin combined with gemcitabine increased by 0.22 QALY over 10 years.
- The cost-effectiveness ratio (ICER) is $52765.59/QALY.
- The combination treatment is not cost-effective at the willingness-to-pay level of $37697.00/QALY.
Takeaway
This study looked at whether a new cancer treatment is worth the money in China, and it found that it's too expensive for the benefits it provides.
Methodology
A Markov model was used to calculate the incremental cost–benefit ratio based on clinical symptoms and disease development.
Limitations
The study relies on clinical trial data rather than real-world studies, and the trial data originated from local hospitals in India without Chinese patients.
Participant Demographics
Patients aged 18 years or older with unresectable gallbladder cancer verified by biopsy or fine needle aspiration.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website